arrow
S

Selena Mimmi

university
H指数:22
被引数:1,177

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

New frontiers in porcine atrioventricular node decellularization: preserving extracellular matrix architecture for biological scaffolds

猪房室结去细胞化研究的新前沿:保留细胞外基质结构以构建生物支架

2026-03-130
OAAI
Neurofilament Light Chain from Neuronally Derived Extracellular Vesicles in Differentiating Parkinson's Disease from Essential Tremor with Resting Tremor

神经元来源的细胞外囊泡中神经丝轻链用于区分帕金森病与静止性震颤为主的特发性震颤

2025-11-110
OAAI
Neuronally Derived Extracellular Vesicles' Oligomeric and p129-α-Synuclein Levels for Differentiation of Parkinson's Disease from Essential Tremor

神经元来源的细胞外囊泡中寡聚型和p129-α-突触核蛋白水平用于区分帕金森病与特发性震颤

2025-04-170
OA
FABP5 is a key player in metabolic modulation and NF-κB dependent inflammation driving pleural mesothelioma
2025-02-270
OAAI
Development of Cyclic Peptides Targeting the Epidermal Growth Factor Receptor in Mesenchymal Triple-Negative Breast Cancer Subtype

靶向表皮生长因子受体的环肽在间充质三阴性乳腺癌亚型中的研究进展

CELLS
IF5.2
2023-04-038
OAAI
SARS CoV-2 spike protein-guided exosome isolation facilitates detection of potential miRNA biomarkers in COVID-19 infections
2023-03-2724
OA
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials

接受埃罗妥珠单抗或卡非佐米联合来那度胺和地塞米松作为挽救疗法的真实复发/难治性多发性骨髓瘤患者的生存风险评分: 临床试验以外的919例分析

2022-07-184
OAAI
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials
2022-06-0111
OA
A novel phage display based platform for exosome diversity characterization
2022-01-0130
PRE